Source comparison
Pe-22-28 vs Selank Amidate: Research Peptide Comparison
The table below summarizes the pharmacological, structural, and practical research distinctions between these two peptides. Primary Mechanism TREK-1 potassium channel antagonist; indirect dopaminergic enhancement GABA-A receptor modulation; enkephalinase inhib
This comparison does not assign a generated winner or score.
- The table below summarizes the pharmacological, structural, and practical research distinctions between these two peptides.
- Primary Mechanism
- TREK-1 potassium channel antagonist; indirect dopaminergic enhancement
- GABA-A receptor modulation; enkephalinase inhibition
- Distinct receptor targets with no pharmacological overlap. Can be used in complementary research protocols
- BDNF Upregulation
- 30–40% increase in hippocampal BDNF at 6 hours post-dose
- Minimal direct BDNF effect; indirect neuroplasticity via stress reduction
- Pe-22-28 is the superior choice for neurogenesis and synaptic plasticity research
- Anxiolytic Profile
- Minimal direct anxiolytic effect; antidepressant-like activity in forced swim test
- Potent anxiolytic without sedation; 40–60% increase in anxiogenic zone time in elevated plus maze
- Selank Amidate is the clear choice for anxiety and stress-response research
- Half-Life
- 4–6 hours (requires twice-daily dosing)
- 8–12 hours (once-daily dosing sufficient)
- Selank Amidate offers logistical advantage in chronic dosing protocols
- Subcutaneous Bioavailability
- 60–70%
- 70–75%
- Comparable; both cross blood-brain barrier at similar rates (15–22% CSF penetration)
- Reconstituted Stability
- 28–30 days at 2–8°C
- 45–60 days at 2–8°C
- Selank Amidate's extended stability reduces waste and simplifies inventory management in long-term studies
- Typical Research Dose Range
- 300–600 mcg per administration
- 200–500 mcg per administration
- Dose requirements similar; both require precise measurement and consistent reconstitution protocols